B7‐1 expression of Langerhans cells is up‐regulated by proinflammatory cytokines, and is down‐regulated by interferon‐γ or by interleukin‐10

Chung‐Hsing ‐H Chang, Masutaka Furue, Kunihiko Tamaki

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Langerhans cells (LC) act as potent antigen‐presenting cells (APC) for primary and secondary T cell‐dependent immune responses. LC express several costimulatory and/or adhesion molecules such as B7/BB1, which has been implicated as one of the important determinants for professional APC. Recent studies have shown that B7/BB1 antigens comprise three distinct molecules termed B7‐1, B7‐2, and B7‐3. We have examined the regulatory properties of B7‐1 expression in LC using various cytokines including interleukin (IL)‐1α, IL‐1β, IL‐2, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐10, interferon (IFN)‐γ, granulocyte/macrophage colony‐stimulating factor (GM‐CSF), and tumor necrosis factor (TNF)‐α. We have demonstrated: 1) that the B7‐1 expression of LC is reproducibly up‐regulated by either GM‐CSF, TNF‐α, IL‐1α, IL‐1β, or IL‐4 in a dose‐ and time‐dependent manner, 2) that GM‐CSF exhibits the most active effect on B7‐1 up‐regulation in each experiment, 3) that IFN‐γ or IL‐10 profoundly inhibits the B7‐1 expression of LC in a dose‐ and time‐dependent manner, and 4) that the down‐regulatory ability of IFN‐γ or IL‐10 neutralizes the activity of up‐regulatory cytokines. The enhancing or inhibitory action of these cytokines on B7‐1 expression occurs selectively because none of the cytokines consistently affects I‐A expression of LC. These data suggest that the B7‐1 expression of LC may be dynamically regulated by these up‐ and down‐regulatory cytokines in normal and inflammatory epidermal microenvironment.

Original languageEnglish
Pages (from-to)394-398
Number of pages5
JournalEuropean Journal of Immunology
Volume25
Issue number2
DOIs
Publication statusPublished - Feb 1995
Externally publishedYes

Fingerprint

Langerhans Cells
Interferons
Down-Regulation
Cytokines
Granulocytes
Interleukin-10
Macrophages
Interleukin-4
Tumor Necrosis Factor-alpha
B7 Antigens
Interleukin-7
Interleukin-5
Interleukin-1
Interleukin-2
Interleukin-6
Up-Regulation

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

B7‐1 expression of Langerhans cells is up‐regulated by proinflammatory cytokines, and is down‐regulated by interferon‐γ or by interleukin‐10. / Chang, Chung‐Hsing ‐H; Furue, Masutaka; Tamaki, Kunihiko.

In: European Journal of Immunology, Vol. 25, No. 2, 02.1995, p. 394-398.

Research output: Contribution to journalArticle

@article{4a848a4b9d404e39a54db4993960bab8,
title = "B7‐1 expression of Langerhans cells is up‐regulated by proinflammatory cytokines, and is down‐regulated by interferon‐γ or by interleukin‐10",
abstract = "Langerhans cells (LC) act as potent antigen‐presenting cells (APC) for primary and secondary T cell‐dependent immune responses. LC express several costimulatory and/or adhesion molecules such as B7/BB1, which has been implicated as one of the important determinants for professional APC. Recent studies have shown that B7/BB1 antigens comprise three distinct molecules termed B7‐1, B7‐2, and B7‐3. We have examined the regulatory properties of B7‐1 expression in LC using various cytokines including interleukin (IL)‐1α, IL‐1β, IL‐2, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐10, interferon (IFN)‐γ, granulocyte/macrophage colony‐stimulating factor (GM‐CSF), and tumor necrosis factor (TNF)‐α. We have demonstrated: 1) that the B7‐1 expression of LC is reproducibly up‐regulated by either GM‐CSF, TNF‐α, IL‐1α, IL‐1β, or IL‐4 in a dose‐ and time‐dependent manner, 2) that GM‐CSF exhibits the most active effect on B7‐1 up‐regulation in each experiment, 3) that IFN‐γ or IL‐10 profoundly inhibits the B7‐1 expression of LC in a dose‐ and time‐dependent manner, and 4) that the down‐regulatory ability of IFN‐γ or IL‐10 neutralizes the activity of up‐regulatory cytokines. The enhancing or inhibitory action of these cytokines on B7‐1 expression occurs selectively because none of the cytokines consistently affects I‐A expression of LC. These data suggest that the B7‐1 expression of LC may be dynamically regulated by these up‐ and down‐regulatory cytokines in normal and inflammatory epidermal microenvironment.",
author = "Chang, {Chung‐Hsing ‐H} and Masutaka Furue and Kunihiko Tamaki",
year = "1995",
month = "2",
doi = "10.1002/eji.1830250213",
language = "English",
volume = "25",
pages = "394--398",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "2",

}

TY - JOUR

T1 - B7‐1 expression of Langerhans cells is up‐regulated by proinflammatory cytokines, and is down‐regulated by interferon‐γ or by interleukin‐10

AU - Chang, Chung‐Hsing ‐H

AU - Furue, Masutaka

AU - Tamaki, Kunihiko

PY - 1995/2

Y1 - 1995/2

N2 - Langerhans cells (LC) act as potent antigen‐presenting cells (APC) for primary and secondary T cell‐dependent immune responses. LC express several costimulatory and/or adhesion molecules such as B7/BB1, which has been implicated as one of the important determinants for professional APC. Recent studies have shown that B7/BB1 antigens comprise three distinct molecules termed B7‐1, B7‐2, and B7‐3. We have examined the regulatory properties of B7‐1 expression in LC using various cytokines including interleukin (IL)‐1α, IL‐1β, IL‐2, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐10, interferon (IFN)‐γ, granulocyte/macrophage colony‐stimulating factor (GM‐CSF), and tumor necrosis factor (TNF)‐α. We have demonstrated: 1) that the B7‐1 expression of LC is reproducibly up‐regulated by either GM‐CSF, TNF‐α, IL‐1α, IL‐1β, or IL‐4 in a dose‐ and time‐dependent manner, 2) that GM‐CSF exhibits the most active effect on B7‐1 up‐regulation in each experiment, 3) that IFN‐γ or IL‐10 profoundly inhibits the B7‐1 expression of LC in a dose‐ and time‐dependent manner, and 4) that the down‐regulatory ability of IFN‐γ or IL‐10 neutralizes the activity of up‐regulatory cytokines. The enhancing or inhibitory action of these cytokines on B7‐1 expression occurs selectively because none of the cytokines consistently affects I‐A expression of LC. These data suggest that the B7‐1 expression of LC may be dynamically regulated by these up‐ and down‐regulatory cytokines in normal and inflammatory epidermal microenvironment.

AB - Langerhans cells (LC) act as potent antigen‐presenting cells (APC) for primary and secondary T cell‐dependent immune responses. LC express several costimulatory and/or adhesion molecules such as B7/BB1, which has been implicated as one of the important determinants for professional APC. Recent studies have shown that B7/BB1 antigens comprise three distinct molecules termed B7‐1, B7‐2, and B7‐3. We have examined the regulatory properties of B7‐1 expression in LC using various cytokines including interleukin (IL)‐1α, IL‐1β, IL‐2, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐10, interferon (IFN)‐γ, granulocyte/macrophage colony‐stimulating factor (GM‐CSF), and tumor necrosis factor (TNF)‐α. We have demonstrated: 1) that the B7‐1 expression of LC is reproducibly up‐regulated by either GM‐CSF, TNF‐α, IL‐1α, IL‐1β, or IL‐4 in a dose‐ and time‐dependent manner, 2) that GM‐CSF exhibits the most active effect on B7‐1 up‐regulation in each experiment, 3) that IFN‐γ or IL‐10 profoundly inhibits the B7‐1 expression of LC in a dose‐ and time‐dependent manner, and 4) that the down‐regulatory ability of IFN‐γ or IL‐10 neutralizes the activity of up‐regulatory cytokines. The enhancing or inhibitory action of these cytokines on B7‐1 expression occurs selectively because none of the cytokines consistently affects I‐A expression of LC. These data suggest that the B7‐1 expression of LC may be dynamically regulated by these up‐ and down‐regulatory cytokines in normal and inflammatory epidermal microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=0028937751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028937751&partnerID=8YFLogxK

U2 - 10.1002/eji.1830250213

DO - 10.1002/eji.1830250213

M3 - Article

C2 - 7533084

AN - SCOPUS:0028937751

VL - 25

SP - 394

EP - 398

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 2

ER -